ArticleBone marrow transplantation2024

Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma.

Chiara De Philippis et al.PubMed ↗Publisher ↗

No numbers read from the abstract.